Proteomic Analysis of Cell Lines and Primary Tumors in Pancreatic Cancer Identifies Proteins Expressed Only In Vitro and Only In Vivo.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
3
8
2021
Statut:
ppublish
Résumé
A limited repertoire of good pancreatic ductal adenocarcinoma (PDAC) models is one of the main barriers in developing effective new PDAC treatments. We aimed to characterize 6 commonly used PDAC cell lines and compare them with PDAC patient tumor samples using proteomics. Proteomic methods were used to generate an extensive catalog of proteins from 10 PDAC surgical specimens, 9 biopsies of adjacent normal tissue, and 6 PDAC cell lines. Protein lists were interrogated to determine what extent the proteome of the cell lines reflects the proteome of primary pancreatic tumors. We identified 7973 proteins from the cell lines, 5680 proteins from the tumor tissues, and 4943 proteins from the adjacent normal tissues. We identified 324 proteins unique to the cell lines, some of which may play a role in survival of cells in culture. Conversely, a list of 63 proteins expressed only in the patient samples, whose expression is lost in culture, may place limitations on the degree to which these model systems reflect tumor biology in vivo. Our work offers a catalog of proteins detected in each of the PDAC cell lines, providing a useful guide for researchers seeking model systems for PDAC functional studies.
Identifiants
pubmed: 32833945
doi: 10.1097/MPA.0000000000001633
pii: 00006676-202009000-00016
doi:
Substances chimiques
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1109-1116Références
Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. 2017;18:1338.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
Ansari D, Torén W, Zhou Q, et al. Proteomic and genomic profiling of pancreatic cancer. Cell Biol Toxicol. 2019;35:333–343.
Knudsen ES, Balaji U, Mannakee B, et al. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut. 2018;67:508–520.
Le Large TYS, Bijlsma MF, Kazemier G, et al. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Semin Cancer Biol. 2017;44:153–169.
Coleman O, Henry M, O'Neill F, et al. A comparative quantitative LC-MS/MS profiling analysis of human pancreatic adenocarcinoma, adjacent-normal tissue, and patient-derived tumour xenografts. Proteomes. 2018;6:45. pii: E45.
pii: e45
Rajamani D, Bhasin MK. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis. Genome Med. 2016;8:38.
Khatri I, Ganguly K, Sharma S, et al. Systems biology approach to identify novel genomic determinants for pancreatic cancer pathogenesis. Sci Rep. 2019;9:123.
González-Boja I, Viúdez A, Goñi S, et al. Omics approaches in pancreatic adenocarcinoma. Cancers (Basel). 2019;11:1052.
Krempley BD, Yu KH. Preclinical models of pancreatic ductal adenocarcinoma. Chin Clin Oncol. 2017;6:25.
Hwang CI, Boj SF, Clevers H, et al. Preclinical models of pancreatic ductal adenocarcinoma. J Pathol. 2016;238:197–204.
Deer EL, González-Hernández J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39:425–435.
Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, et al. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017;12:e0182855.
Nicolle R, Blum Y, Marisa L, et al. Pancreatic adenocarcinoma therapeutic targets revealed by tumor-stroma cross-talk analyses in patient-derived xenografts. Cell Rep. 2017;21:2458–2470.
Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500–503.
Paulo JA, Mancias JD, Gygi SP. Proteome-wide protein expression profiling across five pancreatic cell lines. Pancreas. 2017;46:690–698.
Linge A, Maurya P, Friedrich K, et al. Identification and functional validation of RAD23B as a potential protein in human breast cancer progression. J Proteome Res. 2014;13:3212–3222.
Kaushik P, Henry M, Clynes M, et al. The expression pattern of the phosphoproteome is significantly changed during the growth phases of recombinant CHO cell culture. Biotechnol J. 2018;13:e1700221.
Heberle H, Meirelles GV, da Silva FR, et al. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics. 2015;16:169.
O'Brien N, Conklin D, Beckmann R, et al. Preclinical activity of Abemaciclib alone or in combination with antimitotic and targeted therapies in breast Cancer. Mol Cancer Ther. 2018;17:897–907.
Finn RS, Aleshin A, Dering J, et al. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology. 2013;57:1838–1846.
Gadaleta E, Cutts RJ, Kelly GP, et al. A global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws. Nucleic Acids Res. 2011;39:7900–7907.
Lee YF, Lee CY, Lai LC, et al. CellExpress: a comprehensive microarray-based cancer cell line and clinical sample gene expression analysis online system. Database (Oxford). 2018;2018:bax101.
Yu K, Chen B, Aran D, et al. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nat Commun. 2019;10:3574.
Holst S, Belo AI, Giovannetti E, et al. Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation. Sci Rep. 2017;7:16623.